Evidence map›Paper›PMID 40041752›Full record

ArticleFrontiers in nutrition2024

Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study.

Andreas Kiryttopoulos, Athanasios E Evangeliou, Irene Katsanika, Ioannis Boukovinas, Nikolaos Foroglou, Basilios Zountsas, Angeliki Cheva, Vaios Nikolopoulos, Thomas Zaramboukas, Tomas Duraj and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Efficacy and safety of ketogenic diet in glioblastoma: an updated systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Rethinking corticosteroids use in oncology.Frontiers in pharmacology · 2025
    Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Andreas KiryttopoulosDepartment of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Athanasios E EvangeliouDivision of Child Neurology, St Luke's Hospital, Thessaloniki, Greece.
Irene KatsanikaDepartment of Diet and Nutrition, Papageorgiou General Hospital, Thessaloniki, Greece.
Ioannis BoukovinasBioclinic Thessaloniki Medical Oncology Unit, Thessaloniki, Greece.
Nikolaos ForoglouDepartment of Neurosurgery, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Basilios ZountsasDepartment of Neurosurgery, St Luke's Hospital, Thessaloniki, Greece.
Angeliki ChevaDepartment of Pathology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Vaios NikolopoulosISTODIEREVNITIKI S.A., Surgical Pathology and Cytopathology Laboratories, Thessaloniki, Greece.
Thomas ZaramboukasISTODIEREVNITIKI S.A., Surgical Pathology and Cytopathology Laboratories, Thessaloniki, Greece.
Tomas DurajDepartment of Biology, Boston College, Chestnut Hill, MA, United States.
Thomas N SeyfriedDepartment of Biology, Boston College, Chestnut Hill, MA, United States.
Martha SpiliotiDepartment of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glioblastoma multiforme (GBM) ranks as one of the most aggressive primary malignant tumor affecting the brain. The persistent challenge of treatment failure and high relapse rates in GBM highlights the need for new treatment approaches. Recent research has pivoted toward exploring alternative therapeutic methods, such as the ketogenic diet, for GBM. Methods: A total of 18 patients with GBM, 8 women and 10 men, aged between 34 and 75 years participated in a prospective study, examining the impact of ketogenic diet on tumor progression. The pool of patients originated from our hospital during the period from January 2016 until July 2021 and were followed until January 2024. As an assessment criterion, we set an optimistic target for adherence to the ketogenic diet beyond 6 months. We considered the therapeutic combination successful if the survival reached at least 3 years. Results: Among the 18 patients participating in the study, 6 adhered to the ketogenic diet for more than 6 months. Of these patients, one patient passed away 43 months after diagnosis, achieving a survival of 3 years; another passed away at 36 months, narrowly missing the 3-year survival mark; and one is still alive at 33 months post-diagnosis but has yet to reach the 3-year milestone and is, therefore, not included in the final survival rate calculation. The remaining 3 are also still alive, completing 84,43 and 44 months of life, respectively. Consequently, the survival rate among these patients is 4 out of 6, or 66.7%. Of the 12 patients who did not adhere to the diet, only one reached 36 months of survival, while the rest have died in an average time of 15.7 ± 6.7 months, with a 3-year survival rate of 8.3%. Comparing the survival rates of the two groups, we see that the difference is 58.3% (66.7% versus 8.3%) and is statistically significant with Discussion: The outcomes observed in these patients offer promising insights into the potential benefits of the ketogenic diet on the progression of glioblastoma multiforme when compared to those who did not follow the diet consistently.

Indexed as

braindietglioblastomaketogenicmetabolicmultiformetumor

Identifiers

PMID40041752
PMCPMC11876051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.